{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:22:43Z","timestamp":1766514163181,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00408-019-00283-8","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T12:03:44Z","timestamp":1573041824000},"page":"761-768","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway"],"prefix":"10.1007","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0211-4509","authenticated-orcid":false,"given":"Aravind A.","family":"Menon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis E.","family":"Braverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harrison W.","family":"Farber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"issue":"1","key":"283_CR1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8 N, Humbert M, Vachiery JL et al (2016) 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37(1):67\u2013119","journal-title":"Eur Heart J"},{"issue":"2","key":"283_CR2","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","volume":"137","author":"DB Badesch","year":"2010","unstructured":"Badesch DB, Raskob GE, Elliott CG et al (2010) Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 137(2):376\u2013387","journal-title":"Chest"},{"issue":"5","key":"283_CR3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0002-9629(15)40640-8","volume":"318","author":"AL Curnock","year":"1999","unstructured":"Curnock AL, Dweik RD, Higgins BH, Saadi HF, Arroliga AC (1999) High prevalence of hypothyroidism in patients with primary pulmonary hypertension. Am J Med Sci 318(5):289\u2013292","journal-title":"Am J Med Sci"},{"issue":"4","key":"283_CR4","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1378\/chest.118.4.1224","volume":"118","author":"AC Arroliga","year":"2000","unstructured":"Arroliga AC, Dweik RA, Rafanan AL (2000) Primary pulmonary hypertension and thyroid disease. Chest 118(4):1224\u20131225","journal-title":"Chest"},{"issue":"22","key":"283_CR5","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1001\/jama.285.22.2853","volume":"285","author":"AS Kashyap","year":"2001","unstructured":"Kashyap AS, Kashyap S (2001) Thyroid disease and primary pulmonary hypertension. JAMA 285(22):2853\u20132854","journal-title":"JAMA"},{"issue":"4","key":"283_CR6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/rmed.2001.1260","volume":"96","author":"M Marvisi","year":"2002","unstructured":"Marvisi M, Brianti M, Marani G, Del Borello P, Bortesi ML, Guariglia A (2002) Hyperthyroidism and pulmonary hypertension. Respir Med 96(4):215\u2013220","journal-title":"Respir Med"},{"issue":"5","key":"283_CR7","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1378\/chest.122.5.1668","volume":"122","author":"JW Chu","year":"2002","unstructured":"Chu JW, Kao PN, Faul JL, Doyle RL (2002) High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 122(5):1668\u20131673","journal-title":"Chest"},{"issue":"14","key":"283_CR8","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1001\/archinte.167.14.1526","volume":"167","author":"G Iervasi","year":"2007","unstructured":"Iervasi G, Molinaro S, Landi P et al (2007) Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 167(14):1526\u20131532","journal-title":"Arch Intern Med"},{"issue":"5","key":"283_CR9","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1161\/01.CIR.0000048124.64204.3F","volume":"107","author":"G Iervasi","year":"2003","unstructured":"Iervasi G, Pingitore A, Landi P et al (2003) Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation 107(5):708\u2013713","journal-title":"Circulation"},{"issue":"9","key":"283_CR10","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1253\/circj.CJ-10-0270","volume":"74","author":"Y Miura","year":"2010","unstructured":"Miura Y, Fukumoto Y, Sugimura K et al (2010) Identification of new prognostic factors of pulmonary hypertension. Circ J 74(9):1965\u20131971","journal-title":"Circ J"},{"issue":"6","key":"283_CR11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/MAJ.0b013e31821790f4","volume":"342","author":"S Vallabhajosula","year":"2011","unstructured":"Vallabhajosula S, Radhi S, Alalawi R, Raj R, Nugent K, Cevik C (2011) Hyperthyroidism and pulmonary hypertension: an important association. Am J Med Sci 342(6):507\u2013512","journal-title":"Am J Med Sci"},{"issue":"2","key":"283_CR12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ahj.2009.11.028","volume":"159","author":"A Macchia","year":"2010","unstructured":"Macchia A, Marchioli R, Tognoni G, Scarano M, Marfisi R, Tavazzi L, Rich S (2010) Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am Heart J 159(2):245\u2013257","journal-title":"Am Heart J"},{"issue":"1","key":"283_CR13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/thoraxjnl-2015-207170","volume":"71","author":"M Humbert","year":"2016","unstructured":"Humbert M, Ghofrani HA (2016) The molecular targets of approved treatments for pulmonary arterial hypertension. Thorax 71(1):73\u201383","journal-title":"Thorax"},{"issue":"7","key":"283_CR14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","volume":"112","author":"LJ Rubin","year":"1990","unstructured":"Rubin LJ, Mendoza J, Hood M et al (1990) Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 112(7):485\u2013491","journal-title":"Ann Intern Med"},{"issue":"5","key":"283_CR15","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1378\/chest.13-1864","volume":"145","author":"RR Coeytaux","year":"2014","unstructured":"Coeytaux RR, Schmit KM, Kraft BD et al (2014) Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. Chest 145(5):1055\u20131063","journal-title":"Chest"},{"issue":"6","key":"283_CR16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","volume":"121","author":"RJ Barst","year":"1994","unstructured":"Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS (1994) Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121(6):409\u2013415","journal-title":"Ann Intern Med"},{"issue":"12","key":"283_CR17","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","volume":"106","author":"VV McLaughlin","year":"2002","unstructured":"McLaughlin VV, Shillington A, Rich S (2002) Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106(12):1477\u20131482","journal-title":"Circulation"},{"issue":"5","key":"283_CR18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","volume":"334","author":"RJ Barst","year":"1996","unstructured":"Barst RJ, Rubin LJ, Long WA et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334(5):296\u2013301","journal-title":"N Engl J Med"},{"issue":"6","key":"283_CR19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","volume":"132","author":"DB Badesch","year":"2000","unstructured":"Badesch DB, Tapson VF, McGoon MD et al (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 132(6):425\u2013434","journal-title":"Ann Intern Med"},{"issue":"4","key":"283_CR20","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1164\/rccm.200204-333OC","volume":"167","author":"KP Kuhn","year":"2003","unstructured":"Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM (2003) Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 167(4):580\u2013586","journal-title":"Am J Respir Crit Care Med"},{"issue":"26","key":"283_CR21","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","volume":"373","author":"O Sitbon","year":"2015","unstructured":"Sitbon O, Channick R, Chin KM et al (2015) Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 373(26):2522\u20132533","journal-title":"N Engl J Med"},{"issue":"6","key":"283_CR22","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1378\/chest.119.6.1980","volume":"119","author":"A Ferris","year":"2001","unstructured":"Ferris A, Jacobs T, Widlitz AB, Robyn J, Morse JH (2001) Pulmonary arterial hypertension and thyroid disease. Chest 119(6):1980","journal-title":"Chest"},{"issue":"suppl","key":"283_CR23","first-page":"A630","volume":"155","author":"A Davies","year":"1997","unstructured":"Davies A, Frost A (1997) Epoprostenol-associated thyropathy in PPH patients [abstract]. Am J Respir Crit Care Med 155(suppl):A630","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"283_CR24","first-page":"Supplement 1","volume":"37","author":"Y Gu","year":"2016","unstructured":"Gu Y, Schwarcz MD, Weiss IA (2016) Pulmonary hypertension aggravated by hyperthyroidism: a case report [abstract]. Endocr Rev 37(2):Supplement 1","journal-title":"Endocr Rev"},{"issue":"5","key":"283_CR25","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1378\/chest.116.5.1483","volume":"116","author":"IA Nakchbandi","year":"1999","unstructured":"Nakchbandi IA, Wirth JA, Inzucchi SE (1999) Pulmonary hypertension caused by Graves\u2019 thyrotoxicosis: normal pulmonary hemodynamics restored by 131I treatment. Chest 116(5):1483\u20131485","journal-title":"Chest"},{"issue":"1","key":"283_CR26","first-page":"93","volume":"55","author":"M Marvisi","year":"2013","unstructured":"Marvisi M, Balzarini L, Mancini C, Mouzakiti P (2013) Thyroid gland and pulmonary hypertension. What\u2019s the link? Panminerva Med 55(1):93\u201397","journal-title":"Panminerva Med"},{"issue":"18","key":"283_CR27","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.medcli.2008.09.042","volume":"132","author":"MP Castillo","year":"2009","unstructured":"Castillo MP, Garc\u00eda FH, Montero PB, Gonz\u00e1lez RL, Oca\u00f1a CM, S\u00e1nchez JR (2009) Thyroid dysfunction in patients with pulmonary arterial hypertension. A cohort study of 58 patients. Med Clin (Barc) 132(18):695\u2013700","journal-title":"Med Clin (Barc)"},{"key":"283_CR28","doi-asserted-by":"crossref","unstructured":"Srimatkandada P, Farber HW, Coviello AD (2014) Rapid development of compressive goiter and severe hyperthyroidism in a patient with pulmonary arterial hypertension after treatment with epoprostenol [abstract]. Endocr Rev 35(3)","DOI":"10.4172\/2167-7948.1000176"},{"issue":"176","key":"283_CR29","first-page":"2","volume":"4","author":"P Srimatkandada","year":"2015","unstructured":"Srimatkandada P, Coviello AD (2015) Severe autoimmune hyperthyroidism in two patients with pulmonary arterial hypertension after treatment with epoprostenol. J Thyroid Disord Ther. 4(176):2","journal-title":"J Thyroid Disord Ther."},{"issue":"21_MeetingAbstr","key":"283_CR30","first-page":"Supplement 1","volume":"122","author":"M Funasako","year":"2010","unstructured":"Funasako M, Miyaji K, Sakuma M, Takagi Y, Kyotani S, Nakanishi N (2010) Long-term epoprostenol infusion therapy could induce hyperthyroidism in patients with idiopathic and hereditary pulmonary arterial hypertension [abstract]. Circulation 122(21_MeetingAbstracts):Supplement 1","journal-title":"Circulation"},{"issue":"9630","key":"283_CR31","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","volume":"371","author":"N Galie","year":"2008","unstructured":"Galie N, Rubin LJ, Hoeper MM et al (2008) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371(9630):2093\u20132100","journal-title":"Lancet"},{"issue":"23","key":"283_CR32","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","volume":"117","author":"N Gali\u00e8","year":"2008","unstructured":"Gali\u00e8 N, Olschewski H, Oudiz RJ et al (2008) Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117(23):3010\u20133019","journal-title":"Circulation"},{"issue":"5","key":"283_CR33","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.10-0969","volume":"140","author":"LJ Rubin","year":"2011","unstructured":"Rubin LJ, Badesch DB, Fleming TR et al (2011) Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 140(5):1274\u20131283","journal-title":"Chest"},{"issue":"19","key":"283_CR34","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1016\/S0021-9258(18)63644-0","volume":"244","author":"U Zor","year":"1969","unstructured":"Zor U, Kaneko T, Lowe IP, Bloom G, Field JB (1969) Effect of thyroid-stimulating hormone and prostaglandins on thyroid adenyl cyclase activation and cyclic adenosine 3\u2032, 5\u2032-monophosphate. J Biol Chem 244(19):5189\u20135195","journal-title":"J Biol Chem"},{"key":"283_CR35","first-page":"35","volume":"242","author":"I Virgolini","year":"1987","unstructured":"Virgolini I, Steurer G, Keminger K, Sinzinger H, Kraupp O (1987) Evaluation of prostaglandin receptors in the human thyroid gland. Prog Clin Biol Res 242:35\u201342","journal-title":"Prog Clin Biol Res"},{"issue":"09","key":"283_CR36","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1055\/s-2007-1012390","volume":"18","author":"K Kasai","year":"1986","unstructured":"Kasai K, Hiraiwa M, Suzuki Y et al (1986) Prostacyclin stimulation of adenylate cyclase activity in human thyroid membranes. Horm Metab Res 18(09):625\u2013629","journal-title":"Horm Metab Res"},{"issue":"2","key":"283_CR37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4158\/EP.15.2.116","volume":"15","author":"C Chadha","year":"2009","unstructured":"Chadha C, Pritzker M, Mariash C (2009) Effect of epoprostenol on the thyroid gland: enlargement and secretion of thyroid hormone. Endocr Pract 15(2):116\u2013121","journal-title":"Endocr Pract"},{"issue":"12","key":"283_CR38","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1507\/endocrj.EJ17-0155","volume":"64","author":"M Satoh","year":"2017","unstructured":"Satoh M, Aso K, Nakayama T, Saji T (2017) Effect of treatment with epoprostenol and endothelin receptor antagonists on the development of thyrotoxicosis in patients with pulmonary arterial hypertension. Endocr J 64(12):1173\u20131180","journal-title":"Endocr J"},{"issue":"2","key":"283_CR39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0952-3278(89)90108-7","volume":"37","author":"I Virgolini","year":"1989","unstructured":"Virgolini I, Hermann M, Sinzinger H (1989) Decrease of the prostaglandin I2 binding capacity in thyroids from patients with Graves\u2019 disease. Prostaglandins Leukot Essent Fatty Acids 37(2):121\u2013128","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"1","key":"283_CR40","first-page":"75","volume":"26","author":"K Yoh-ichiro","year":"1987","unstructured":"Yoh-ichiro K, Kanemaru Y, Noguchi T, Onaya T (1987) Circulating prostacyclin and thromboxane in patients with Graves\u2019 disease. Prostaglandins Leukot Essent Fatty Acids 26(1):75\u201384","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"12","key":"283_CR41","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1089\/thy.2011.2112.ed","volume":"21","author":"TH Brix","year":"2011","unstructured":"Brix TH, Heged\u00fcs L (2011) The complexity of the etiology of autoimmune thyroid disease is gravely underestimated. Thyroid 21(12):1289\u20131292","journal-title":"Thyroid"},{"key":"283_CR42","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ijcard.2012.09.064","volume":"168","author":"A Frey","year":"2013","unstructured":"Frey A, Kroiss M, Berliner D et al (2013) Prognostic impact of subclinical thyroid dysfunction in heart failure. Int J Cardiol 168:300\u2013305","journal-title":"Int J Cardiol"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-019-00283-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00408-019-00283-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-019-00283-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T17:45:49Z","timestamp":1611769549000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00408-019-00283-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["283"],"URL":"https:\/\/doi.org\/10.1007\/s00408-019-00283-8","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"type":"print","value":"0341-2040"},{"type":"electronic","value":"1432-1750"}],"subject":[],"published":{"date-parts":[[2019,11,6]]},"assertion":[{"value":"10 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"AA.M and L.E.B have no conflicts of interest to disclose. S.S has received consultant fees from Actelion Pharmaceuticals and speaker fees from Actelion Pharmaceuticals, Bayer AG and United Therapeutics Corporation. H.W.F. has received research grants from Gilead; Actelion Pharmaceuticals US Inc; and United Therapeutics Corporation and consulting fees from Gilead; Actelion Pharmaceuticals US, Inc; United Therapeutics Corporation; Bayer AG; Arena, Boehringer-Ingelheim;\u00a0and Bellerophon.\u00a0He also has served on a speaker\u2019s bureau or given presentations on behalf of Actelion Pharmaceuticals US, Inc; Gilead; and Bayer AG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}